RESEARCH ARTICLE

AGE AND GENDER RELATED MORTALITY AND OUTCOME OF COVID 19 POSITIVE PATIENTS

Suhail Mansoor, Ghulam Jeelani Romshoo and Abroo Bashir
Department of Medicine, GMC Anantnag.

Abstract

Background: This study was aimed to evaluate the age and gender related mortality and outcome of covid 19 positive patients in order to further strengthen the management of covid 19 patients as the insights from these data will be useful in determining preventive measures and treatment policies of covid 19 patients.

Methodology: This was a retrospective observational study done in adult covid positive patients admitted in Tertiary Care Hospital from first May 2020 to 30 June 2021. The age related mortality and outcome in these patients was analyzed.

Results: A total of 816 adult covid-19 positive patients were admitted in a Tertiary care hospital from May 2020 to June 2021. Among the patients, 53.55% were males and 46.44% were females. The mean of the age involved was 57.96 years. The most common presenting symptom was fever (85%) followed by cough (70%) and shortness of breath (40%). Approximately 20% of patients presented with nonspecific complaints (including generalized aches, pains, body aches, myalgias etc). All age groups were affected equally (29% in 15-50yr, 37% in 51-65yr, 33% in 66-100yr). Maximum patients (70%) affected were more than 50 yr of age. About 73.4% were discharged, 6% were referred, 20% expired. So, overall hospital mortality was 20%. Further, Maximum (86%) of covid positive patients expired in age group of above 50 yrs. Further, Male and Female Mortality was also same in covid positive patients.

Conclusion: Males and females were affected equally by Covid-19 disease with no sex predilection. Fever was the main presenting symptom. All age groups were affected equally but mortality was more in elderly age group. Further, mortality is same in male and female covid positive patients with no gender predilection.

Introduction:
Coronavirus disease-2019 (COVID-19) emerged in China in December 2019 and engulfed the whole world in a very short period of time. COVID-19 announced in March 2020 as a pandemic by the World Health Organization (WHO). Worldwide till now around 95 million patients have been infected with more than 2 million deaths. It has infected more than 10 million people in India with 1.5 lakh deaths.1,2,3
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19. SARS-CoV-2 spreads from person to person through respiratory particles during coughing, sneezing or speaking. Because both larger particles (droplets) and smaller particles (aerosols) are concentrated within a short distance, the likelihood of transmission decreases with increased ventilation and physical distancing.

Cough, fever, fatigue, headache, myalgias and diarrhea are the common initial symptoms of coronavirus disease 2019 (COVID-19). The most common symptom of severe disease is dyspnea and is often accompanied by hypoxemia. Severe illness usually begins approximately 1 week after the onset of symptoms. Soon after the onset of dyspnea and hypoxemia in severe COVID-19, progressive respiratory failure develops in many patients. These patients commonly meet the criteria for the acute respiratory distress syndrome (ARDS). ARDS is defined as the acute onset of bilateral infiltrates, severe hypoxemia, and lung edema that is not fully explained by cardiac failure or fluid overload. Older age, cardiovascular disease, chronic lung disease, diabetes, and obesity are risk factors for complications of COVID-19.

On the basis of a suggestive clinical history and the detection of SARS-CoV-2 RNA in respiratory secretions, diagnosis of COVID-19 can be established. Chest radiography should be performed and bilateral consolidations or ground-glass opacities are commonly seen.

The definition for epidemiologic purposes in severe COVID-19 in adults is dyspnea, a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao2:Fio2) of less than 300 mm Hg, or infiltrates in more than 50% of the lung field. Renal failure and thrombosis are well-recognized complications of severe COVID-19. Dexamethasone, Remdesivir, Endotracheal intubation have a role in Management.

In patients with COVID-19 disease, the prevalence of mortality among hospitalized patients varies from 6.3 to 26.85% in different parts of the world. For critical conditions, early identification of risk factors is urgently needed, not only to identify the defining epidemiological and clinical characteristics with greater precision, but also to provide and facilitate the appropriate supportive care and prompt access to the intensive care unit (ICU) if needed. For higher severity and mortality in patients with COVID-19, gender is a risk factor independent of age and susceptibility.

However, the age-related pattern of COVID-19 fatality is different from that of other respiratory viral infections. As in COVID-19 positive patients, the severity pattern is often described as a U-shaped curve: the morbidity and mortality are concentrated at extreme age groups (younger children and the elderly). Population-based studies of seasonal influenza have typically shown this type of mortality distribution according to age.

During the pandemic, one of the most critical issues dealt by public health and clinical professionals is the spectrum of illness severity. This really affects the triage, diagnostic decision making, therapeutic decision making and prognostic expectations. Therefore, understanding COVID-19 associated morbidity and mortality with relation to age is important. As there is paucity of studies regarding gender and age related mortality in COVID-19 positive patients, so we conducted this study to provide data to further strengthen the management of COVID-19 positive patients.

**Methodology:**
This was an observational retrospective study of COVID-19 positive patients. It included patients who were admitted in the Tertiary Care Hospital, GMC Anantnag from 1st May 2020 to 30 June 2021. The data was collected from online portal which was maintained by computer section of Department of Medicine. The data was updated each day regarding outcome of the admitted patients. The data was analysed by statistician. All the patients admitted were moderate to severe confirmed COVID-19 patients whose real-time reverse-transcription polymerase chain reaction assay findings for nasal or pharyngeal swab specimens were positive.

Moderate Illness: Clinical or radiographic evidence of lower respiratory tract disease; oxygen saturation ≥94%. Diagnostic testing.

Severe Illness: Oxygen saturation <94%; respiratory rate ≥30 breaths/min; lung infiltrates >50%. Diagnostic testing.
Data related to age related mortality and outcome of all the patients who were admitted during the study period was collected from their electronic medical records, daily progress charts, nursing notes of the patients. Patients’ age, sex, complaints at the time of presentation was noted and analyzed. Total of 816 covid-19 positive patients were admitted. Adult patients were further divided into age-groups of 15 to 50, 51 to 65, and 66-100 and their age related mortality and outcome was seen. Mortality was calculated until patients were hospitalised or discharged from the hospital. This study did not include post discharge mortality in long covid syndrome patients.

**Results:**

**Table 1:** Gender distribution among covid positive patients.

| Gender | N  | Percentage |
|--------|----|------------|
| Male   | 437| 53.55      |
| Female | 379| 46.44      |
| Total  | 816|            |

Table 1 shows that a total of 816 covid positive patients were admitted. Out of which about half 437 (53%) were males and about half 379 (46%) were females with no sex predilection. The mean of the age involved was 57.96 years.

**Table 2:** Age specific distribution among covid positive patients.

| Age     | N  | Percentage |
|---------|----|------------|
| 15-50   | 238| 29.16      |
| 51-65   | 304| 37.25      |
| 66-100  | 274| 33.57      |

Table 2 suggests that out of 816 patients admitted, about 238 (29%) were in age group of 15-50 yrs. Maximum of patients about 578 (70%) were above 50 years of age.

**Table 3:** Patient outcome among covid positive patients.

| Covid positive patients | N  | Percentage |
|-------------------------|----|------------|
| Discharged              | 599| 73.40      |
| Referred                | 52 | 6.37       |
| Expired                 | 165| 20.22      |

Table 3 suggests that the mortality among 816 admitted covid positive patients was about 20% (165). Maximum 599 (73%) of patients were discharged. Only 52 (6.37%) were referred.

**Table 4:** Age specific distribution among expired covid positive patients.

| Covid positive patients (n) | Expired | percentage |
|-----------------------------|---------|------------|
| 15-50                       | 23      | 13.93      |
| 51-100                      | 142     | 86.06      |

Table 4 suggests that maximum 142 (86%) of covid positive patients expired in age group of above 50 yrs. About 23 (13%) expired in age group of 15-50 yr.

**Table 5:** Association between Age and Mortality in covid positive patients.

| Age group (Covid positive patients) | Expired | Non-Expired | P value <.05 |
|-------------------------------------|---------|-------------|--------------|
| 15-50                               | 23      | 215         |              |
| 51-100                              | 142     | 436         |              |

Table 5 shows mortality is higher in elderly age group and the results are highly significant (p value <0.05). Statistical Analysis: chi square statistic is 23.21. p value is <0.00001. chisquare statistic with Yates correction is 22.29. p value is <0.00001. p<.05
Table 6: Clinical features of covid positive patients.

| Clinical features                          | N   | Percentage |
|-------------------------------------------|-----|------------|
| Fever                                     | 693 | 85         |
| Cough                                     | 571 | 70         |
| Shortness of breath                       | 362 | 42         |
| Non specific complaints (generalised pains, bodyaches, myalgias) | 163 | 20         |

Table 6 depicts that fever was the main presenting symptom (85%) followed by cough (70%). About 42% were having shortness of breath. Approximately 20% of patients were having non specific complaints like generalised pains, bodyaches, myalgias.

Table 7: Gender specific mortality in covid positive patients.

| Covid positive | Expired | Non -Expired | P > .05 |
|----------------|---------|--------------|---------|
| Males          | 84      | 433          |         |
| Females        | 81      | 298          |         |
| Total          | 165     |              |         |

Table 7 depicts mortality is almost same in Males and Females with no gender predilection. The result is statistically insignificant P > .05.

Discussion:

Coronavirus is a large family of viruses with a range of illnesses from common cold to pneumonia like severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS)\(^1\). The epidemiological features of patients with COVID-19 have been recently reported\(^2\). Further, clinical features of patients with COVID-19 have also been reported\(^3\). However, little data on the prognostic factors of COVID-19 have been reported. Analyses by gender and sex may help in the development of strategies for prevention for the COVID-19 pandemic\(^4\).

This study retrospectively analysed age and gender related mortality and outcome of COVID-19 positive patients. Total of 816 confirmed adult COVID-19 patients were admitted in the study period.
In our study, Males and females were of almost equal proportion among admitted covid positive patients. This is in contrast to study\(^3\) where 60% of all admitted patients were males and in contrast to other studies where male predisposition was found for this disease across various ethnic and racial groups\(^{28,29,30}\).

In our study, fever was the main presenting symptom followed by cough, shortness of breath. This is similar to study\(^16\).

In our study, 29.16% were of age-group of 15–50 years, 37.25% in the age-group 51–65 years and only about 33.57% were above 65 years age-group. This is in contrast to study\(^3\) where 42.1% were of age-group of 18–50 years, 35% in the age-group 51–64 years, and only about 23% were above 65 years age-group. But similar to the studies from other parts of the world where most of the nonsurvivors were also from a much older age-group\(^{29,30,31}\).

The ICU mortality of COVID-19 patients varies from 8.0 to 66.7% in different studies\(^32\). In study\(^3\), the hospital mortality was 18.2% and ICU mortality was 36.1. In our study, the hospital mortality was 20%. Similar mortality rates have been reported in other studies from US, Spain, Italy, and few studies from China\(^{28,29,33}\). However, from China, there are other studies which depict lower overall mortality rates\(^34\).

Association between age and mortality in covid positive patients was seen in elderly age group in our study. And the results are highly significant. This is similar to the studies\(^ {20,35,36,37,37} \). Elderly patients have a higher mortality rate due to high CFR and symptomatic infection rate among covid-19 positive patients\(^ {37,7} \). Several studies have reported old age to be a significant risk factor for COVID-19 mortality\(^ {37,7} \). In patients with age of more than 70 yrs and more or equal to 60 yrs in Korea and Italy respectively, approximately 80% and 90% of deaths have occurred in them respectively\(^ {35,36} \). In an animal study, SARS-CoV-2 infection caused more severe interstitial pneumonia and viral replication in tissues of lungs of old monkeys than in those of young monkeys\(^ {38}\). Vulnerability to an infection in the elderly is usually explained by immunosenescence and chronic subclinical systemic inflammation also known as inflammaging in immunopathology\(^ {39,40} \). Some scientists have claimed that there is the biologically plausible pathomechanism that explains the difference in vulnerability to SARS-CoV-2 infection and this is called antibody-dependent enhancement (ADE)\(^ {41,42,43,44} \). ADE is a well-known cascade of events by which viruses may infect susceptible cells through interactions between virions complexed with antibodies and Fc receptors, where they are more extensively endocytosed and eventually replicated more efficiently\(^ {45} \). The antibodies that bind to virions could be neutralizing or non-neutralizing antibodies, which were previously formed in response to SARS-CoV-2 or other coronaviruses with similar antigenicity to that of SARS-CoV-2. There was also the fact that the seroprevalence of community-acquired coronaviruses among adults was very high (90 – 100%) but not in pediatrics which was further presented as an evidence\(^ {46,47} \). There are several other factors related to aging that could be reasons for higher morbidity and mortality in the elderly in addition to the aging immunity or ADE. Further, The average number of comorbid conditions steadily increased with age. Because of the chronic illnesses and the impact of congregate housing in older adults living in long-term care facilities, they are at the highest risk\(^ {48,49} \).

In our study, mortality is same in covid positive males and females. But this is in contrast to the study done by JIN JM et al\(^18\) where male mortality is more as compared to female mortality and Men with COVID-19 are more at risk for worse outcomes and death, independent of age.

**Conclusion:**

Overall, there was no sex predilection. Fever was the main presenting symptom. All age groups were affected equally but mortality was more in elderly age group. Further, mortality is same in male and female covid positive patients with no gender predilection. Age was more determinantal factor for mortality than sex. The above study gives an important clue about the triage and management of covid 19 patients. Even mild to moderate covid disease in elderly warrants critical care in ICU admission. It also downcourages the homebased isolation and management of elderly covid 19 patients.

**Bibliography:**

1. World Health Organization (WHO). Coronavirus disease (COVID-2019) situation report -110. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200509covid-19-sitrep-110. pdf ?sfvrsn=3b92992c_6. Accessed 29 May 2020.
2. Worldometer info. World/Countries/India; 2020. Available from: https://www.worldometers.info/coronavirus/country/india [Accessed on January 17, 2020].
3. Aggarwal R, Bhatia R, Kulshrestha K, Soni KD, Viswanath R, Singh AK et al. Clinicoepidemiological Features and Mortality Analysis of Deceased Patients with COVID-19 in a Tertiary Care Center. Indian J Crit Care Med 2021; 25(6):622–628
4. Rajesh T. Gandhi, John B. Lynch, and Carlos del Rio. n engl j med 383:18 nejm.org October 29, 2020
5. Paules CI, Marston HD, Fauci AS. Coronavirus infections — more than just the common cold. JAMA 2020; 323: 707
6. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
8. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9.
9. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307: 2526-33.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
11. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180: 934-43.
12. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
13. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 382-6.
14. Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 2020; 43: 1392-8.
15. Wong HYF, Lam HYS, Fong AH-T, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology 2020; 296(2): E72-E78.
16. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-42.
17. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J Community Health 2020;45(6):1270–1282. DOI: 10.1007/s10900-020-00920-x
18. Bouvier NM. The future of influenza vaccines: a historical and clinical perspective. Vaccines (Basel) 2018;6:58.
19. Seung-Ji Kang and Sook In Jung. Age-Related Morbidity and Mortality among Patients with COVID-19 Infect Chemother. 2020 Jun;52(2):154-164 https://doi.org/10.3947/ic.2020.52.2.154 pISSN 2093-2340-eISSN 2092-6448
20. Centers for Disease Control and Prevention. Interim guidance for rapid antigen testing for SARS-CoV-2. 2020 (https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html).
21. Drost C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. (2003) 348:1967–76. doi: 10.1056/NEJMoa030747
22. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. (2012) 367:1814–20. doi: 10.1056/NEJMoa1211721
23. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. (2020) 382:1199–207. doi: 10.1056/NEJMoa2001316
24. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9
25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
26. Connie B. Newman, MD, FACP, FAMWA Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFEY Study. JOURNAL OF WOMEN’S HEALTH Volume 30, Number 1, 2021
27. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395(10239):1763–1770. DOI: 10.1016/S0140-6736(20)31189-
28. Rivera-Izquierdo M, Del Carmen Valero-Ubierna M, R-delAmo JL, Fernández-García Má, Martínez-Díaz S, Tahery-Mahmoud A, et al. Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: a retrospective observational study. PLoS One 2020;15(6):e0235107. DOI: 10.1371/journal.pone.0235107
29. Palmieri L, Vanacore N, Donfrancesco C, Lo Noce C, Canevelli M, Punzo O, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci 2020;75(9):1796–1800. DOI: 10.1093/gerona/glaa146.
30. Pellaud C, Grandmaison G, Pham Huu Thien HP, Hoa Phong PH, Baumberger M, Carrel G, et al. Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area – a retrospective cohort study. Swiss Med Wkly 2020;150:w20314. DOI: 10.4414/smw.2020.2031
31. Quah P, Li A, Phua J. Mortality rates of COVID-19 in the intensive care unit: a systematic review of the emerging literature. J Crit Care 2020;55:123–129. DOI: 10.1016/j.jcrc.2020.03.015.
32. Biagi A, Rossi L, Malagoli A, Zanni A, Sticcozzii C, Comastri G, et al. Clinical and epidemiological characteristics of 320 deceased patients with COVID-19 in an Italian Province: a retrospective observational study. J Med Virol 2020;92(11):2718–2724. DOI: 10.1002/jmv.26147
33. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis 2020;20(7):776–777. DOI: 10.1016/S1473-3099(20)30244-9.
34. Korea Centers for Disease Control and Prevention (KCDC). Status of COVID-19 in Korea. Available at: http://ncov.mohw.go.kr/bdBoardList_Real.do?brdId=1&brdGubun=11&ncvContSeq=&contSeq=&board_id=&gubun=. Accessed 29 May 2020.
35. Istituto Superiore di Sanità. Epidemia COVID-19. Available at: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-surveglianza-integrata-COVID-19_2-aprile-2020.pdf. Accessed 10 May 2020
36. Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China. Mech Ageing Dev 2020;188:111255.
37. Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, Xiao C, Lv Q, Gong S, Liu J, Song Z, Qu Y, Xue J, Wei Q, Liu M, Wang G, Wang S, Yu H, Liu X, Huang B, Wang W, Zhao L, Wang H, Ye F, Zhou W, Zhen W, Han J, Wu G, Jin Q, Wang J, Tan W, Qin C. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med 2020;3:93-7.
38. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000;31:578-85.
39. Bonafé M, Prattichizzo F, Giuliani A, Storci G, Sabbatini J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev 2020.
40. Kadkhoda K. COVID-19: an immunopathological view. MSphere 2020;5:e00344-20.
41. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020;1:6.
42. Tiloca B, Soggia A, Musella V, Britti D, Sanguinetti M, Urbani A, Roncada P. Molecular basis of COVID-19 relationships in different species: a one health perspective. Microbes Infect 2020;22:218-20.
43. Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly 2020;150:w20249.
44. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003;13:387-98.
45. Gorse GJ, Patel GB, Vitale JN, O’Connor TZ. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. Clin Vaccine Immunol 2010;17:1875-80.
46. Prill MM, Iwane MK, Edwards KM, Williams JY, Weinberg GA, Staat MA, Willby MJ, Talbot HK, Hall CB, Szilagyi PG, Griffin MR, Curns AT, Erdman DD; New Vaccine Surveillance Network. Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls. Pediatr Infect Dis J 2012;31:235-40.
47. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020;80:e14-8.
48. Kim T. Improving preparedness for and response to coronavirus disease 19 (COVID-19) in long-term care hospitals in Korea. Infect Chemother 2020;52:133-41.